QURE News

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

QURE FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

מועד אחרון לתביעה הייצוגית נגד QURE: רוזן, משרד עורכי דין מוביל, מעודד משקיעים ב-uniQure N.V עם הפסדים העולים על 100,000 דולר לקבל ייעוץ משפטי לפני המועד החשוב ב-13 באפריל בתביעה ייצוגית בניירות ערך – QURE

QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Kyndryl Holdings, Inc. (KD), uniQure N.V. (QURE), and REGENXBIO Inc. (RGNX) Announced by Holzer & Holzer, LLC

QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of uniQure N.V. to Contact the Firm Today!